NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PA-17-077 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites R18 grant applications for research that demonstrates how health information technology (IT) can improve patient-centered health outcomes and quality of care in primary care and other ambulatory settings through the scale and spread of successful, health IT-enabled practice models that use patient-reported outcome (PRO) measures to achieve these objectives.
Funding Opportunity PAR-17-074 from the NIH Guide for Grants and Contracts. The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of expensive, specialized, commercially available instruments or integrated systems that cost at least $50,000. There is no maximum price requirement; however, the maximum award is $600,000. Types of instruments supported include, but are not limited to: X-ray diffractometers, mass and nuclear magnetic resonance (NMR) spectrometers, DNA and protein sequencers, biosensors, electron and light microscopes, cell sorters, and biomedical imagers.
Funding Opportunity RFA-RM-17-001 from the NIH Guide for Grants and Contracts. The purpose of this small research grant Funding Opportunity Announcement (FOA) is to foster collaboration between computational scientists, metabolomics experts, and biomedical researchers in developing, piloting, and/or validating novel bioinformatic approaches that address current analytical hurdles in metabolomics data. A goal of providing powerful approaches that will be useful to biomedical researchers, as well as bioinformaticians, is particularly encouraged. Projects are not intended to supplement ongoing metabolomics analyses, but to provide a tool for broader use by the biomedical research community. Projects are expected to use existing, publicly available metabolomics data and complement the efforts and resources of the Common Fund Metabolomics Program.
Funding Opportunity RFA-AT-17-001 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit UG3/UH3 phased cooperative agreement research applications to conduct efficient, large-scale pragmatic clinical trial Demonstration Projects within the NIH-DoD-VA Pain Management Collaboratory on non-pharmacological approaches to pain management and other co-morbid conditions in U.S. military personnel, veterans and their families. This program will be referred to as the NIH-DoD-VA Pain Management Collaboratory program. Awards made under this FOA will initially support a two-year milestone-driven planning phase (UG3), with possible transition to a pragmatic trial Demonstration Project implementation phase (UH3). UG3 projects that have met the scientific milestone and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The overall goal of this initiative, jointly supported by the NIH, DoD, and VA, is to develop the capacity to implement cost-effective large-scale clinical research in military and veteran health care delivery organizations focusing on non-pharmacological approaches to pain management and other comorbid conditions. The NIH, DoD, and VA expect to: establish a Coordinating Center that will provide national leadership and technical expertise for all aspects of health care system (HCS_- focused research including assistance to UG3/UH3 grant applicants. Primary outcomes of treatment interventions include assessing pain and pain reduction, ability to function in daily life, quality of life, and medication usage/reduction/discontinuation. Secondary outcomes focusing on assessing comorbid conditions or those co-occurring with high frequency in this population are also of interest under the FOA.
Funding Opportunity RFA-AT-17-002 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications for a Coordinating Center (CC) to provide national leadership for the NIH-DoD-VA Health Care Systems (HCS) Research Collaboratory program on non-pharmacological approaches to pain management and comorbidities in U.S. military personnel, veterans and their families. For brevity, this initiative will be referred to as the NIH-DoD-VA Pain Management Collaboratory. Coordinating Center applicants will need to: 1) develop, adapt, and adopt technical and policy guidelines and best practices for the effective conduct of research in partnership with health care systems focused on military personnel, veterans, and their families; 2) work collaboratively with and provide technical, design, and other support to Demonstration Project teams, to develop and implement a pragmatic trial protocol; and 3) disseminate widely Collaboratory-endorsed policies and best practices and lessons learned in the Demonstration Projects for implementing research within health care settings. The Coordinating Center will also serve as the central resource for the activities of the NIH-DoD-VA Pain Management Collaboratory program, including providing administrative support for a Steering Committee and its subcommittees.
Funding Opportunity PAR-17-079 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages health services research designed to increase the public health impact of Food and Drug Administration (FDA)-approved pharmacotherapies for the treatment of alcohol use disorder. Significant progress is needed in developing generalizable, scalable, cost-effective strategies to move these evidence-based interventions into the mainstream of alcohol use disorder treatment, in both general medical and specialty care settings. The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to conduct hypothesis-driven research to identify effective methods for increasing the utilization of currently-available medications, by addressing their acceptability (to prescribers and patients), perceived effectiveness, affordability, and feasibility of use within existing care delivery systems.
Notice NOT-NS-17-010 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-17-078 from the NIH Guide for Grants and Contracts. The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex/gender influences and/or sex and gender factors in human health and illness, including basic, preclinical, clinical and behavioral studies. Of special interest are studies relevant to understanding the significance of biological sex on cells and tissue explants; comparative studies of male and female tissues, organ systems and physiological systems; sex-based comparisons of pathophysiology, biomarkers, gene expression, clinical presentation and prevention and treatment of diseases. The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from Goals 1 through 3 of the NIH Strategic Plan for Women's Health Research.
Notice NOT-HS-17-005 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-17-073 from the NIH Guide for Grants and Contracts. Data from clinical studies of metformin in a variety of patient populations suggest that it may have other effects, besides being an antihyperglycemic agent, which warrant further attention in translational aging research. The objective of this FOA is to support research projects (R01), including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformins human physiologic and cellular effects that would be useful in identifying novel molecular targets.
Notice NOT-DE-17-005 from the NIH Guide for Grants and Contracts
Notice NOT-DE-17-008 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-072 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Revision applications from currently active NIA and NINR institutional training grants that propose a new research emphasis on Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) or propose to expand the scope of AD/ADRD research on their existing training grant. The revision should provide for the seamless integration of AD/ADRD into the overall scientific emphasis of the ongoing training program.
Funding Opportunity RFA-NS-17-017 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to support the genetic discovery, replication and validation of disease causing mutations, risk variants and genetic modifiers which contribute to the pathophysiology, proteinopathies and clinical heterogeneity representative of the neurological syndromes that are classified under the broad spectrum of Frontotemporal Degeneration (FTD). The FTD Sequencing Consortium FOA will support whole genome sequencing, replication and functional variant validation studies of FTD case/control and family-based cohorts identified through clinical diagnosis or autopsy confirmation.
Funding Opportunity RFA-MD-17-003 from the NIH Guide for Grants and Contracts. The purpose of the Research Centers in Minority Institutions (RCMI) Program is to expand the national capacity for research in the health sciences by providing cooperative agreement support to institutions that offer doctorate degrees in the health professions or in a health-related science and have a historical and current commitment to educating underrepresented students, and for institutions that deliver health care services, providing clinical services to medically underserved communities. The primary goals of the RCMI specialized centers are to: (1) enhance institutional research capacity within the areas of basic biomedical, behavioral, and/or clinical research; (2) enable all levels of investigators to become more successful in obtaining competitive extramural support, especially from NIH, particularly on diseases that disproportionately impact minority and other health disparity populations; (3) foster environments conducive to career enhancement with a special emphasis on development of new and early career investigators; (4) enhance the quality of all scientific inquiry and promote research on minority health and health disparities; and (5) establish sustainable relationships with community-based organizations that will partner with the RCMI Institution.
Funding Opportunity RFA-AI-16-082 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide funding to expand specific activities under the U.S.-South Africa Program for Collaborative Biomedical Research (R01). The purpose of the opportunities under the revision application is to enhance the pool of investigators in South Africa who are from underrepresented backgrounds in the country's workforce and who are engaged in collaborative research activities in the areas of tuberculosis (TB), HIV/AIDS biomedical and behavioral science, and HIV-related co-morbidities, including malignancies.
Funding Opportunity RFA-AI-16-083 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to provide funding to expand specific activities under the U.S.-South Africa Program for Collaborative Biomedical Research (U01). The purpose of the opportunities under the revision application is to enhance the pool of investigators in South Africa who are from underrepresented backgrounds in the country's workforce and who are engaged in collaborative research activities in the areas of tuberculosis (TB), HIV/AIDS biomedical and behavioral science, and HIV-related co-morbidities, including malignancies.
Funding Opportunity RFA-DK-17-501 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement requests submission of a Revision application for the Human Islet Research Network Coordinating Center (HIRN-CC). The HIRN-CC was awarded by NIDDK in 2014 (RFA-DK-13-013), and consists of a single U01 that is charged with coordinating the activities of four related but distinct basic science research consortia. The HIRN program was designed to be a flexible network that rapidly responds to new advances and opportunities in human islet research. The network's composition and scientific scope change over time, resulting in changes to the number, size and nature of member consortia supported by the HIRN coordinating center. Accordingly, the HIRN-CC was envisioned as a project that would evolve over time to support the needs of this expanding and ever-changing network of human islet researchers. Since the inception of HIRN, the network has grown in size and complexity. For this reason, NIDDK is providing an opportunity for the HIRN-CC to submit a Revision application that will support increased needs across the HIRN. This supplemental award is intended to support additional pilot projects that will seed new and innovative research collaborations, and that will expand the development of novel shared resources required by HIRN investigators and the community. NIDDK uses the cooperative agreement funding mechanism supporting the HIRN-CC for a variety of projects requiring significant input from and oversight by NIDDK program staff. Although some requests for expansion or redirection of a project that are considered within the scope of the original specific aims can be handled administratively, more substantial changes in direction and increases in funding require peer review.
Funding Opportunity PAR-17-071 from the NIH Guide for Grants and Contracts. This FOA seeks low-cost, pragmatic research projects that leverage electronic clinical records to conduct studies that address novel health services questions about the treatment of alcohol use disorders (AUD) in routine clinical care settings. Although projects may be supplemented by other data sources, it is expected that major data collection activities will be integrated into, or obtained from, routine clinical records and other electronic resources, such as patient registries, electronic health records, data warehouses, billing data, pharmacy records, and/or administrative records. Projects should address questions with direct relevance for improving clinical care for patients with AUD, while contributing to an understanding of the current utility and remaining barriers to using electronic health records in the conduct of AUD treatment services research.
Funding Opportunity RFA-CA-17-009 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to create a network of Drug Resistance and Sensitivity Centers (DRSCs) to develop innovative strategies to study mechanisms of tumor resistance or sensitivity to anticancer therapy. It is hoped that such studies will permit future efforts to identify and exploit these phenomena in clinical settings.